These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15116243)

  • 21. Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide.
    Ma S; Ma CC
    Vascul Pharmacol; 2014 Nov; 63(2):63-70. PubMed ID: 25139660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiated control of deranged nitric oxide metabolism: a therapeutic option in sepsis?
    Lupp C; Baasner S; Ince C; Nocken F; Stover JF; Westphal M
    Crit Care; 2013 May; 17(3):311. PubMed ID: 23751085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.
    Gresele P; Marzotti S; Guglielmini G; Momi S; Giannini S; Minuz P; Lucidi P; Bolli GB
    Diabetes Care; 2010 Jun; 33(6):1262-8. PubMed ID: 20299485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelium negatively modulates the vascular relaxation induced by nitric oxide donor, due to uncoupling NO synthase.
    Bonaventura D; Lunardi CN; Rodrigues GJ; Neto MA; Vercesi JA; de Lima RG; da Silva RS; Bendhack LM
    J Inorg Biochem; 2009 Oct; 103(10):1366-74. PubMed ID: 19699534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitric oxide donors for cardiovascular implant applications.
    Naghavi N; de Mel A; Alavijeh OS; Cousins BG; Seifalian AM
    Small; 2013 Jan; 9(1):22-35. PubMed ID: 23136136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis.
    Gori T
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32295055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitric oxide-releasing drugs.
    Napoli C; Ignarro LJ
    Annu Rev Pharmacol Toxicol; 2003; 43():97-123. PubMed ID: 12540742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor.
    Vilahur G; Pena E; Padró T; Badimon L
    Thromb Haemost; 2007 Apr; 97(4):650-7. PubMed ID: 17393029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applications for nitric oxide in halting proliferation of tumor cells.
    Reynolds MM; Witzeling SD; Damodaran VB; Medeiros TN; Knodle RD; Edwards MA; Lookian PP; Brown MA
    Biochem Biophys Res Commun; 2013 Feb; 431(4):647-51. PubMed ID: 23337501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitric oxide-producing polyurethanes.
    Jun HW; Taite LJ; West JL
    Biomacromolecules; 2005; 6(2):838-44. PubMed ID: 15762649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effects.
    Vilahur G; Baldellou MI; Segalés E; Salas E; Badimon L
    Cardiovasc Res; 2004 Mar; 61(4):806-16. PubMed ID: 14985078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus.
    Schäfer A; Flierl U; Vogt C; Menninger S; Tas P; Ertl G; Bauersachs J
    Pharmacol Res; 2007 Sep; 56(3):217-23. PubMed ID: 17669665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Endothelioprotective properties of L-arginine in a nitric oxide deficiency model].
    Pokrovskiĭ MV; Pokrovskaia TG; Kochkarov VI; Artiushkova EB
    Eksp Klin Farmakol; 2008; 71(2):29-31. PubMed ID: 18488903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational analysis of nitric oxide biotransport to red blood cell in the presence of free hemoglobin and NO donor.
    Deonikar P; Abu-Soud HM; Kavdia M
    Microvasc Res; 2014 Sep; 95():15-25. PubMed ID: 24950305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppressing NADPH oxidase-dependent oxidative stress in the vasculature with nitric oxide donors.
    Selemidis S
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1395-401. PubMed ID: 18954334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelium-dependent NO-mediated vasodilation in humans is attenuated by peripheral alpa1-adrenoceptor activation.
    Kamper AM; de Craen AJ; Westendorp RG; Blauw GJ
    Vasc Health Risk Manag; 2005; 1(3):251-6. PubMed ID: 17319111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nitric oxide and regulation of vascular tone: pharmacological and physiological considerations.
    McHugh J; Cheek DJ
    Am J Crit Care; 1998 Mar; 7(2):131-40; quiz 141-2. PubMed ID: 9509227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease.
    Redington AE
    Eur J Pharmacol; 2006 Mar; 533(1-3):263-76. PubMed ID: 16466650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of nitric oxide donors in schizophrenia: Basic studies and clinical applications.
    Pitsikas N
    Eur J Pharmacol; 2015 Nov; 766():106-13. PubMed ID: 26435027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders.
    Gresele P; Momi S
    Cardiovasc Drug Rev; 2006; 24(2):148-68. PubMed ID: 16961726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.